Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation Trial

Cigarette smoking is an important cause of illness and death among persons with HIV (PWH). This project will study the impact of adding contingency management (use of financial rewards) to receiving medications and counseling on promoting smoking abstinence and other health outcomes among PWH. As treatments will be provided by clinical pharmacists and other team members in HIV clinics, factors relevant for implementing this model to inform real-world practice will also be evaluated.

Start Date30 Sep 2027

Sponsor / Collaborator

Yale University

[+1]

NCT07809854

/ Not yet recruitingPhase 4IIT

Evaluating an Innovative Tobacco Treatment Approach for Veterans in Substance Use Disorder Treatment

Veterans with substance use disorders smoke at extraordinarily high rates and have high rates of smoking-related death and disease. It is essential to provide tobacco treatment for Veterans with substance use disorders, but there are unfortunately low rates of smoking treatment engagement within the VA for those with substance use disorders. The goal of this project is to generate preliminary evidence for a smoking intervention program called "Concurrent Substance and Tobacco Outpatient Program" or Co-STOP. Co-STOP aims to increase tobacco treatment use and effectiveness for Veterans in outpatient substance use treatment. The investigators hypothesize that Co-STOP, relative to standard tobacco treatment, will increase tobacco treatment use and quit attempts. This research will help the VA develop effective strategies to promote smoking treatment use and abstinence in Veterans with substance use disorders who smoke, thereby improving rates of morbidity and mortality in Veterans with substance use disorders.

Start Date01 Apr 2027

Sponsor / Collaborator

VA Office of Research and Development

[+1]

NCT07754578

/ Not yet recruitingPhase 2

High-Dose Nicotine Replacement Therapy for Quitting Cigarettes and E-cigarettes

This randomized clinical trial evaluates the effectiveness of augmented-dose combination nicotine replacement therapy (NRT) versus standard-dose NRT and no-NRT control for cessation of dual combustible cigarette (CC) and electronic cigarette (EC) use. Adults who currently engage in dual use and are motivated to quit both products will be assigned to one of three 12-week interventions: (1) no pharmacotherapy (behavioral support only), (2) standard-dose NRT (21 mg nicotine patch + 4 mg lozenges, 5-20/day), or (3) augmented-dose NRT (21 mg + 14 mg patches + 4 mg lozenges, 5-30/day). All groups receive evidence-based behavioral support through the EX Program. Primary outcomes include biochemically confirmed dual abstinence and CC-only abstinence at 12 and 24 weeks. A subset of participants will provide blood and saliva samples to assess DNA damage biomarkers associated with tobacco use and cessation.

Start Date01 Nov 2026

Sponsor / Collaborator

The Medical University of South Carolina

[+2]

100 Clinical Results associated with Nicotine

100 Translational Medicine associated with Nicotine

100 Patents (Medical) associated with Nicotine

32,954

Literatures (Medical) associated with Nicotine

01 Feb 2027·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Integrative network toxicology and virtual knockout analysis suggest TSNA-associated molecular features in large cell neuroendocrine carcinoma

Article

Author: Yang, Gang ; Yu, Jiahui ; Yin, Liuzhe ; Liu, Zhicheng ; Xiong, Zhe ; Wu, Wei

OBJECTIVE:

Electronic nicotine delivery systems (ENDS) may contain or generate low levels of tobacco-specific nitrosamines (TSNAs), including N-nitrosoanatabine (NAT) and N-nitrosoanabasine (NAB), under certain thermal conditions. Given the uncertain long-term carcinogenic effects of ENDS, this study explored potential molecular associations between TSNA-related exposure signatures and LCNEC using an integrative computational framework.

METHODS:

We integrated network toxicology, clinical transcriptomics (GSE1037), and single-cell RNA sequencing (GSE269942) to identify key targets. Protein-protein interaction (PPI) networks and hub genes were established. Interactions between TSNAs and hub targets were validated using molecular docking and 100-ns molecular dynamics (MD) simulations. Potential network-level perturbation effects were explored via scTenifoldKnk-based virtual knockouts (vKO), diagnostic ROC analysis, and CIBERSORT-based immune infiltration analysis.

RESULTS:

Network analysis identified EGFR, CASP3, CCND1, STAT3, and SRC as central toxicological sensors, with MD simulations suggesting stable predicted interactions with NAT and NAB.The PI3K-Akt pathway emerged as a recurrently enriched pathway linking predicted TSNA targets with LCNEC-associated transcriptomic alterations. Single-cell profiling localized the transcriptomic reprogramming-characterized by IGFBP2 upregulation and EDNRB silencing-specifically to malignant LCNEC clusters. EDNRB (AUC=0.954) and IGFBP2 (AUC=0.855) demonstrated high diagnostic accuracy. vKO simulations suggested that IGFBP2 and EDNRB may be associated with network-level perturbations involving growth-related and immune-related genes.Drug screening anchored this signature to nicotine and prioritized EGFR-related inhibitors and natural compounds as hypothesis-generating candidates for further validation.

CONCLUSION:

This study proposes a hypothesis-generating computational model in which TSNA-associated target networks converge on PI3K-Akt-related signaling and the IGFBP2/EDNRB expression axis in LCNEC.These findings provide exploratory molecular evidence that may inform future experimental studies on TSNA-related lung cancer biology and potential biomarker discovery.

01 Jan 2027·JOURNAL OF NEUROSCIENCE METHODS

Passive nicotine vapor exposure model in mice reveals translationally relevant dose-dependent cotinine levels and withdrawal behaviors

Article

Author: La, Tu ; de Guglielmo, Giordano ; Carrette, Lieselot L G ; George, Olivier ; Ambroggi, Frédéric ; Mosquera, Joseph ; China, Lindsey ; Martinez, Angelica R ; Zahedi, Sélène

BACKGROUND:

Nicotine use disorder and electronic cigarette use remain major public health concerns. While passive vapor exposure systems have been developed in rats, efforts to replicate these approaches in mice have produced inconsistent results, with substantial variability in dosing regimens and limited validation using behavioral and biological markers of nicotine dependence.

NEW METHOD:

We characterized a passive vapor exposure model in C57BL/6 J mice using nicotine dose-response paradigms and spontaneous withdrawal measures. Mice (N = 69) were exposed to 0, 5, 15, or 50 mg/mL nicotine vapor in a 1:1 PG/VG base for 1 h, followed by serum cotinine measurement. A separate cohort (N = 18) received nicotine or vehicle vapor for two weeks, followed by assessment of somatic signs, locomotion, anxiety-like behavior, body temperature, and thermal nociception 24 h post-cessation.

RESULTS:

Serum cotinine increased dose-dependently, with males exhibiting higher levels than females at the highest concentration. Both nicotine groups displayed elevated somatic withdrawal scores driven by paw and body tremors. The 15 mg/mL group additionally showed locomotor sensitization and increased nociceptive thresholds. Core body temperature and anxiety-like behavior in the open field were unaffected across all doses.

COMPARISON WITH EXISTING METHODS:

Our system achieves equivalent or greater cotinine levels within a single 1-hour session across a range of translationally relevant doses, without requiring invasive delivery methods.

CONCLUSIONS:

This model produces biologically relevant nicotine exposure and somatic dependence in mice. Affective and physiological withdrawal components were not detected under these conditions and may require longer exposure durations or alternative assays to fully manifest.

01 Jan 2027·TOXICOLOGY

Toxicity of tobacco products and nicotine on neutrophil host defense: An in vivo and in vitro approach

Article

Author: Gonçalves, Carlos Eduardo ; Yonamine, Mauricio ; Gil, Cristiane Damas ; Farsky, Sandra Helena Poliselli ; Fock, Ricardo Ambrósio ; Sandri, Silvana ; Borges, Pâmela Pacassa ; Scharf, Pablo ; Paranhos, Beatriz Aparecida Passos Bismara ; Makiyama, Edson Naoto

Although heated tobacco products (HTPs) reduce combustion-derived toxicants, increasing evidence indicates that they still induce adverse biological effects whose mechanisms remain poorly understood. We previously showed that HTP exposure impairs, whereas conventional cigarette (CC) exposure exacerbates, neutrophil influx into the inflamed synovium of mice with antigen-induced arthritis (AIA). Here, we investigated the effects of HTP vapor, CC smoke, and vaporized nicotine on neutrophil production and function. Naive and AIA mice and bone marrow (BM)-derived neutrophils were exposed to HTP vapor, CC smoke, or vaporized nicotine. Exposures were carried out in nicotine-equivalent model conditions. In vivo, CC exposure enhanced granulopoiesis, whereas HTP exposure impaired this process, as determined by the numbers of blast cells, immature neutrophils, and mature segmented neutrophils in the BM. In contrast, nicotine exposure increased the numbers of blast cells and band neutrophils and reduced mature circulating neutrophils; nonetheless, it did not alter neutrophil recruitment into the inflamed joint cavity. In BM-derived neutrophils, HTP vapor, CC smoke, and nicotine differentially affected neutrophil function. All exposures increased reactive oxygen species production. CC smoke increased ionomycin-induced extracellular DNA release, whereas both HTP vapor and CC smoke impaired chemotaxis. In contrast, nicotine enhanced neutrophil migratory capacity. STAT3 signaling was modulated following CC smoke and nicotine exposure but not HTP vapor. Together, these in vivo and in vitro findings demonstrate that CC smoke, HTP vapor, and nicotine differentially regulate neutrophil biology. Furthermore, these suggest that other constituents besides nicotine contribute substantially to HTP-induced immunotoxicity, providing mechanistic evidence that these products directly interfere with innate immune responses under inflammatory conditions.

233

News (Medical) associated with Nicotine

14 Oct 2026

·www.prnewswire.com

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its clinical development program for VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist. Vanda's Phase III clinical study, VP-VQW-765-3201 (Study 3201), which evaluated VQW-765 for the on-demand treatment of acute anxiety in adults with social anxiety disorder, did not meet its primary endpoint. Study 3201 (NCT07221578)1 was a multicenter, randomized, double-blind, placebo-controlled Phase III study conducted at approximately 30 clinical sites in the U.S. The study randomized 546 adults 18 to 65 years of age with a current diagnosis of social anxiety disorder and elevated baseline scores on the Liebowitz Social Anxiety Scale and Public Speaking Anxiety Scale. Participants received a single oral dose of VQW-765 or placebo in a 1:1 ratio and were then challenged with a psychosocial stress test, the standardized Trier Social Stress Test (TSST). The TSST induces acute stress by having participants prepare (anticipation phase) and then deliver (performance phase) an interview-style presentation to a panel that gives no feedback or encouragement. The primary endpoint was the level of distress during the performance phase of the TSST in the female population, as measured by the Subjective Units of Distress Scale (SUDS), on which participants rate their nervousness or distress from 0 to 100, with higher scores indicating greater distress. Female participants who received VQW-765 did not show a statistically significant difference from those who received placebo. The study also did not meet the key secondary endpoint of SUDS during the performance phase of the TSST in the full (male and female) population. Study 3201 was designed to confirm the findings of Vanda's earlier Phase II clinical study, VP-VQW-765-2201 (Study 2201), in which participants with a history of performance anxiety who received VQW-765 reported numerically lower stress levels during the TSST than those who received placebo. The Phase III results did not confirm those findings. "We are disappointed that Study 3201 did not confirm the earlier Phase II findings2 for VQW-765 in patients with social anxiety disorder," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda Pharmaceuticals. "We thank the participants, investigators and site staff who made this study possible." Given these results, the VQW-765 program is on hold pending further analysis of the full dataset. About VQW-765 VQW-765 is a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist, with potential use for the treatment of psychiatric disorders. VQW-765 binds and enhances the activity of one type of nicotinic receptors composed of a pentameric assembly of the alpha 7 subtype. While nicotine can also bind this receptor, the binding affinity of VQW-765 is much higher than that of nicotine, making it a potent and specific molecule for the alpha 7 receptor. VQW-765, formerly known as AQW-051, was licensed to Vanda from Novartis. About Performance Anxiety Over 20% of the U.S. population is estimated to experience debilitating performance anxiety that ranges from public speaking to test taking, writer's block and musical performance. The most common type of performance anxiety is public speaking anxiety. People with performance anxiety report that the condition can hinder or even threaten their professional career of choice. Similarly, musicians report that performance anxiety makes them perform at levels below their capabilities. Currently, there is no FDA-approved drug treatment available for performance anxiety and general anti-anxiolytic drugs tend to be sedating, which is not preferred in a performance situation. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit and follow us on X @vandapharma. References 1. ClinicalTrials.gov NCT07221578. 2. He Y, Polymeropoulos CM, Mohrman MA, et al. Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial. Br J Psychiatry. 2025;227(1):473-480. doi:10.1192/bjp.2025.84 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Various statements in this press release, including but not limited to statements regarding Vanda's clinical development plans for VQW-765; Vanda's clinical development plans for the rest of its late-stage pipeline and the estimated prevalence in the U.S. of performance anxiety are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the outcome of Vanda's analysis of the full dataset from Study 3201; and the accuracy of the estimates of the prevalence in the U.S. of performance anxiety. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at . All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Corporate Contact: Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc. 202-734-3400 [email protected] Jim Golden / Jack Kelleher / Dan Moore Collected Strategies [email protected] Follow us on X @vandapharma SOURCE Vanda Pharmaceuticals Inc. 21% more press release views with Request a Demo

Clinical ResultPhase 2Phase 3

08 Oct 2026

·www.sciencedaily.com

Nearly 30,000 people tested quit-smoking methods. One stood out

Nicotine e-cigarettes appear to help more smokers quit than patches, gum, and several other common approaches, according to a major review of 80 clinical trials. Researchers say regulated vaping products are not risk-free, but may be a significantly less harmful alternative for people who would otherwise continue smoking.An updated Cochrane review has found that nicotine e-cigarettes may help more people stop smoking than several commonly used approaches, including nicotine gum, nicotine patches, behavioral support, or trying to quit without assistance. Smoking remains the world's leading cause of preventable disease and death. According to the World Health Organization (WHO), it is responsible for more than seven million deaths each year, including 1.6 million deaths among non-smokers exposed to second-hand smoke. The findings come from a living systematic review, meaning researchers continually update the analysis as new evidence becomes available. The latest version included 80 randomized controlled trials involving 29,861 participants, with nine new trials added in this update. Nicotine Vapes Outperform Patches and Gum The researchers found high-certainty evidence that nicotine e-cigarettes produced higher quit rates than nicotine replacement therapy (NRT), such as patches and gum. For every 100 people, nicotine e-cigarettes resulted in about 4 additional people successfully quitting. Nicotine e-cigarettes also performed better than non-nicotine cigarettes, leading to about 2 additional quitters per 100 people. People given e-cigarettes also had higher quit rates than those who received no support or behavioral support (such as individual counseling and group programs). However, the researchers had less confidence in this comparison because of potential bias in how some of the studies were designed. "We have very strong evidence that regulated nicotine e-cigarettes are substantially less harmful than smoking," says Dr. Jamie Hartmann-Boyce, senior author of the review from the University of Massachusetts Amherst. "Based on the consistency of the findings here, it's clear that they are a proven and viable option for people wishing to quit traditional cigarettes. This update includes 9 new trials and our main conclusions haven't changed." What the Evidence Says About Vaping Risks Researchers found no evidence that using e-cigarettes to quit smoking increased the risk of serious harm, although they emphasize that longer-term research is still needed. The conclusions apply specifically to regulated, nicotine-containing e-cigarettes. Illicit products and e-cigarettes containing other substances, such as THC, may present different risks. "It's worth highlighting that our review looks at regulated e-cigarettes containing nicotine, but many of those available on the market do not meet these standards," says Dr. Hartmann-Boyce. "Unlicensed e-cigarettes are potentially dangerous, with issues including unstable batteries and harmful chemicals. Anyone looking to use e-cigarettes to quit smoking should only purchase devices that have been tested and approved by their country's regulatory body. Lists of regulated devices are available from the FDA in the US and MHRA in the UK." Major health organizations and agencies, including the WHO, continue to warn that e-cigarettes expose users to nicotine and other chemicals that can be harmful. Health officials have also raised concerns that e-cigarette use among children and young people can lead to nicotine addiction and later use of tobacco products. A Step Away From Cigarettes, Not a Risk-Free Endpoint The researchers stress that e-cigarettes may not be the best quitting method for everyone. People who want to stop smoking are encouraged to speak with stop-smoking support services or their clinicians about the most appropriate approach. Vaping still carries health risks. However, the authors say those risks are much smaller than the dangers associated with continuing to smoke cigarettes. Dr. Nicola Lindson, lead author of the review based at the University of Oxford, reflects that: "Quitting smoking is hard, and a lot of people who smoke will have tried many times to quit smoking and been unsuccessful. For that reason, it is important that there are a number of different options available to help somebody quit, which could encourage them to keep trying. Although nicotine vapes are unlikely to be completely risk-free, they are less harmful than smoking, and that is the most important comparison to make for people who are still smoking tobacco." Dr. Hartmann-Boyce views switching to e-cigarettes as a possible stage in the process of moving away from smoking, rather than necessarily the final destination. "For somebody who is already addicted to nicotine through cigarettes, having a safer alternative like an e-cigarette is something worth considering, especially when other quit aids have proven unsuccessful. We are currently working on a review of interventions to help people quit vaping, which could be the next step along for people looking to transition to a lower-harm product before quitting nicotine altogether."

Clinical Result

05 Oct 2026

·www.prnewswire.com

Truth Initiative Names Dr. Vaughan Rees as Chief Research Officer

Harvard public health scientist and addiction research leader will lead scientific agenda spanning tobacco, nicotine and broader addiction challenges WASHINGTON, Oct. 5, 2026 /PRNewswire/ -- Truth Initiative, the nation's largest nonprofit public health organization dedicated to preventing youth and young adult nicotine addiction and empowering quitting for all, today announced that Dr. Vaughan Rees will join the organization as Chief Research Officer on October 27, succeeding Dr. Barbara Schillo. Continue Reading Truth Initiative Rees joins Truth Initiative from the Harvard T.H. Chan School of Public Health, where he has served as Director of the Center for Global Tobacco Control since 2015 and is a Senior Lecturer on Social and Behavioral Sciences. A public health scientist and research leader with more than 25 years of experience, Rees brings deep expertise in addiction and behavioral science, tobacco control and regulatory science, prevention, implementation science and public health policy. At Truth Initiative, he will lead the Schroeder Institute, the organization's research and scientific enterprise. "Vaughan is an exceptional scientist and leader whose breadth of expertise is ideally matched to where Truth Initiative is headed," said Kathy Crosby, CEO and president of Truth Initiative. "We have built an extraordinary foundation in tobacco and nicotine science, and as the addiction landscape evolves, we have an opportunity to apply our science, innovation and behavior change expertise more broadly to the addiction challenges affecting young people today, including those related to nicotine, cannabis, opioids and other emerging risks. Vaughan brings the scientific leadership and perspective to help us build on that foundation, advance proven public health interventions that prevent and address addiction, and ensure rigorous evidence informs public health policy, regulation and solutions that improve lives." As Chief Research Officer, Rees will guide the continued evolution of Truth Initiative's scientific agenda through the Schroeder Institute, advancing a multidisciplinary research portfolio encompassing tobacco and nicotine, addiction science, behavioral health, emerging nicotine products, cannabis, polysubstance use and other evolving public health challenges, particularly among youth and young adults. He will also help expand opportunities for externally funded research and scientific collaboration and strengthen Truth Initiative's ability to translate rigorous science into evidence-based interventions and real-world public health impact. "I am honored to join Truth Initiative, an organization with such a strong record of using science to improve public health," said Rees. "I look forward to working with its talented scientists and leaders to better understand the processes that drive addiction and, importantly, translate what we learn into more effective prevention, treatment and public health policy." Throughout his career, Rees has led interdisciplinary research programs and built national and international collaborations spanning addiction science, tobacco regulatory science and public health. At Harvard, his work has included laboratory-based tobacco research examining tobacco products, consumer behavior and questions relevant to tobacco regulation, giving him deep experience at the intersection of science, product regulation and public health policy . As Principal Investigator, he has directed a multidisciplinary research portfolio supported by more than $12 million in external funding and contributed to collaborative research programs exceeding $50 million. He has advised the U.S. Food and Drug Administration, the World Health Organization Framework Convention on Tobacco Control and the National Academies of Sciences, Engineering, and Medicine. Rees' research reflects the breadth he will bring to Truth Initiative. In addition to extensive work in tobacco and nicotine, his research has examined cannabis and nicotine co-use, cannabis retailer availability and broader drug-attributable harms. Rees also brings a strong commitment to developing the next generation of public health scientists. He has mentored more than 60 master's students, 12 doctoral students, postdoctoral fellows and early-career investigators. Rees succeeds Dr. Barbara Schillo, whose excellent leadership has helped build Truth Initiative's strong scientific foundation and advance its national reputation for rigorous, policy-relevant public health research. "Barbara's contributions to Truth Initiative and to the field have been extraordinary," Crosby said. "Her leadership has strengthened our science, developed exceptional researchers and ensured that evidence remains at the heart of our work. We are deeply grateful for all she has contributed, and Vaughan will build on an incredibly strong foundation as we enter this next chapter." About Truth Initiative Truth Initiative® is a national nonprofit public health organization committed to a future free from lifelong addiction, fostering healthier lives and a more resilient nation. Our mission is to prevent youth and young adult nicotine addiction and empower quitting for all. Through our evidence-based, market-leading cessation intervention, EX® Program, and national public education campaigns, we lead the fight against youth and young adult tobacco use. Learn more at truthinitiative.org. SOURCE Truth Initiative 21% more press release views with Request a Demo

Executive Change

100 Deals associated with Nicotine

External Link

KEGG	Wiki	ATC	Drug Bank
D03365	Nicotine	N07BA01	DB00184

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Smoking Cessation	South Korea	SAEHAN PHARM	28 Aug 2007
Tobacco Use Disorder	Australia	Johnson & Johnson Pacific Pty Ltd.	27 Nov 2001
Nicotine Dependence	United States	Haleon US Capital LLC	13 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acral Lentiginous Malignant Melanoma	Phase 3	United States	McNeil AB	01 Mar 2011
Dyskinesia, Drug-Induced	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Parkinson Disease	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Lung Cancer	Phase 1	United States	Pfizer Inc.	16 Jun 2017
disorder of aging	Preclinical	China	The Shenzhen Institutes of Advanced Technology	07 Feb 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05014282 (CTgov)	Not Applicable	Smoking Cessation	512	Counseling+Nicotine patch (Standard Treatment)	sbdjcrjtjt = jejgrzeynd bebsdwlyge (vdclqkzjwl, jmqcjwnzpl - jrfngkunqu) View more	-	25 Sep 2026
				Smartphone-delivered automated treatment+Nicotine patch (Automated Treatment)	sbdjcrjtjt = dfrrnnmtzn bebsdwlyge (vdclqkzjwl, ylutqfgnbp - rqkvraoyee) View more
NCT05430334 (CTgov)	Not Applicable	Nicotine Dependence	142	e-liquid 5 (Placebo - Combination Five - 0μg/s Nicotine Flux)	bmcsjebymd(xaffbeeicy) = jnzuradirm dfmbblxopb (nqbwunbfue, wfjcaaasrb - lonvddwiaw) View more	-	18 Sep 2026
				e-liquid 1 (Combination One - 15μg/s Protonated Nicotine Flux)	bmcsjebymd(xaffbeeicy) = mshqmzsswe dfmbblxopb (nqbwunbfue, hgpdwjshmf - bhqcdplaxh) View more
NCT02720445 (MIND, CTgov)	Phase 2	Mild cognitive disorder	348	Nicotine Transdermal Patch (Nicotine Transdermal Patch)	paxzvgmlva(pgdtofktgi) = qcncgtkmwh ydefviungt (ckhqoczgoi, 0.4969) View more	-	17 Sep 2026
				Placebo Patch (Placebo Patch)	paxzvgmlva(pgdtofktgi) = cguljgsgoq ydefviungt (ckhqoczgoi, 0.5065) View more
NCT05206435 (SHINE, CTgov)	Phase 4	Nicotine Dependence	183	Electronic Cigarette (Electronic Cigarettes)	nuakqdhduq(ahupwatjlg) = cwoimjvzjj lqeqeflhkw (cpivoqwpvj, .28) View more	-	20 Aug 2026
				Nicotine Lozenge (Nicotine Lozenges)	nuakqdhduq(ahupwatjlg) = wzwsmalvkr lqeqeflhkw (cpivoqwpvj, .24) View more
NCT01622998 (STEP, CTgov)	Phase 4	Smoking Cessation	303	NicoDerm Patch (Standard Transdermal NRT Group (UC))	zvbidmdvpl = vcvfisqxrm snwzguxffp (nrspzmjkkk, wtomaawmlh - zetlcqgfzb) View more	-	14 Aug 2026
				NicoDerm Patch (Titrated Transdermal NRT Group (EXP))	zvbidmdvpl = mmyzuklgyo snwzguxffp (nrspzmjkkk, ditoeigttp - tjbukerzby) View more
NCT00962988 (CTgov)	Phase 4	Stroke \| Ischemic Attack, Transient \| Smoking Cessation ... View more	194	Cost-Free Pharmacotherapy Group (Cost-Free Group)	ggkxqbcbnz = fsvigbhabl vyvwcykpam (adifljbhuq, nlxezolyye - qfkihohhvs) View more	-	10 Aug 2026
				Prescription Only Group (Prescription Only Group)	ggkxqbcbnz = tchnlucisi vyvwcykpam (adifljbhuq, jiwbhvxqgi - tpzuwfqkza) View more
NCT05004662 (CTgov)	Not Applicable	Smoking Cessation	502	Nicotine Patch+Counseling (Standard Treatment)	dinnwmohxg = zmpijorqfb aycbsajrmy (kktresnohl, aenkezvfzj - zinlnszlad) View more	-	04 Aug 2026
				Nicotine patch+Smartphone-delivered automated treatment (Automated Treatment)	dinnwmohxg = sqlsxbccbg aycbsajrmy (kktresnohl, gxyusjbgji - uvqufzxanw) View more
NCT05130788 (CTgov)	Not Applicable	Smoking Cessation	150	Nicotine Replacement Therapy (NRT) (Intervention Group A (Aim 2))	jkdrpnvabq = gthwdlgmxt pjmsaitrpv (qkieybszxn, uouftmczpb - pwiyenbxri) View more	-	31 Jul 2026
				Nicotine Replacement Therapy (NRT) (Control Group (Aim 2))	bjactwxczs = wzgtlkmmdp uqykttlwtf (kwimqvstsz, tlpobcfqqi - smueozdwfk) View more
NCT03691350 (CTgov)	Early Phase 1	-	66	Bronchoscopy with Bronchoalveolar Lavage (Group I (Usual Cigarette Brand))	urgismuwhz(raronjsrnm) = xyprocermg qgltqkaony (nyxbwappbl, 0.3059) View more	-	23 Apr 2026
				Electronic Cigarette (Group II (SREC With Nicotine))	urgismuwhz(raronjsrnm) = hkfdhnhxxv qgltqkaony (nyxbwappbl, 0.2939) View more
NCT06051474 (CTgov)	Phase 4	Smoking Cessation \| Smoking \| Nicotine Dependence	23	Nicotine Replacement Product	izchalqxiu = ckjcoczkyv rnzoomvmzj (javcewoirv, lbtpwfrvui - tjjafggrps) View more	-	16 Apr 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis